Edition:
United States

Key Developments: Chiasma Inc (CXS.F)

CXS.F on Frankfurt Stock Exchange

2.67EUR
4 May 2016
Change (% chg)

€-0.20 (-6.84%)
Prev Close
€2.87
Open
€2.67
Day's High
€2.67
Day's Low
€2.67
Volume
--
Avg. Vol
913
52-wk High
€25.34
52-wk Low
€2.67

Search Stocks

Latest Key Developments (Source: Significant Developments)

Chiasma announces FDA acceptance for filing of new drug application for Octreotide Capsules in Acromegaly
Monday, 17 Aug 2015 07:00am EDT 

Chiasma Inc:Says that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.  Full Article

Chiasma Inc. announces closing of initial public offering and full exercise of underwriters' option to purchase additional shares
Tuesday, 21 Jul 2015 04:07pm EDT 

Chiasma Inc:Says closing of its initial public offering of 7,319,750 shares of common stock at a price of $16.00 per share, before underwriting discounts, which includes the exercise in full by the underwriters of their option to purchase up to 954,750 additional shares of common stock.All of the common stock was offered by Chiasma. Chiasma's stock is listed on The NASDAQ Global Select Market under the ticker symbol CHMA.Barclays Capital Inc. and Cowen and Company, LLC acted as joint book-running managers for the offering.William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. acted as co-managers.  Full Article

Chiasma Inc prices initial public offering of common stock
Wednesday, 15 Jul 2015 07:49pm EDT 

Chiasma Inc:Announces the pricing of its initial public offering of 6,365,000 shares of common stock at a price of $16.00 per share, before underwriting discounts.Says Barclays Capital Inc. and Cowen and Company, LLC acted as joint book-running managers for the offerin.Says William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. acted as co-managers.  Full Article

BRIEF-Chiasma updates FDA's complete response letter for Mycapssa(tm)

* Chiasma provides update regarding FDA's complete response letter for Mycapssa(tm) new drug application

Search Stocks